<DOC>
	<DOCNO>NCT01932970</DOCNO>
	<brief_summary>This multicenter , multiple-dose , single-arm , open-label study assess impact serum correct calcium level switch patient cinacalcet etelcalcetide ( AMG 416 ) .</brief_summary>
	<brief_title>Study Assess Impact Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism ( SHPT ) Switch From Cinacalcet Etelcalcetide</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria Subject 18 year age old time inform consent . Subject must receive maintenance hemodialysis 3 time weekly least 8 week . Subject must SHPT define mean 3 consecutive central laboratory screen predialysis serum parathyroid hormone ( PTH ) value ≥ 200 pg/mL , measurement obtain 3 different calendar week 4week screen period receive cinacalcet . Subject must mean 3 consecutive central laboratory screen predialysis serum correct calcium ( cCa ) value ≥ 7.5 mg/dL , measurement obtain 3 different calendar week 4week screen period receive cinacalcet . Subject must stable dose cinacalcet screen ( define dose change within 4 week prior screen ) . Other Inclusion Criteria may apply . Exclusion Criteria Currently receive treatment another investigational device drug study , less 30 day since end treatment another investigational device drug study ( ) . Subject receive AMG 416 prior clinical trial AMG 416 ( also know KAI4169 ) . Subject know sensitivity product component AMG 416 administered dosing . Subject unwilling use effective contraception study , woman , period 3 month last dose AMG 416 . Subject pregnant nursing . Anticipated schedule parathyroidectomy study period . Subject receive parathyroidectomy within 6 month prior dose . Other Exclusion Criteria may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Secondary Hyperparathyroidism ( SHPT ) , chronic kidney disease ( CKD ) , hemodialysis , parathyroid hormone ( PTH ) , hypocalcemia , bone mineral metabolism</keyword>
</DOC>